Condition: Squamous Cell Carcinoma of the Oral Cavity · Sponsor: Gliknik Inc.
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Maryland Greenebaum Cancer Center | Baltimore, Maryland, United States | — |
| National Institute of Oncology | Budapest, Hungary | — |
| Semmelweis University | Budapest, Hungary | — |
| University of Debrecen Clinical Center | Debrecen, Hungary | — |
| Bacs-Kiskun County Teaching Hospital | Kecskemét, Hungary | — |
| Medical Center of the University of Pecs | Pécs, Hungary | — |
| Oncology Center of Prof. Franciszek Lukaszczyk in Bydgoszcz | Bydgoszcz, Poland | — |
| Swietokrzyskie Oncology Center in Kielce | Kielce, Poland | — |
| Clinical Oncology Center | Omsk, Russia | — |
| Rostov Oncology Research Institute | Rostov-on-Don, Russia | — |
| Leningrad Regional Oncology Center | Saint Petersburg, Russia | — |
| Oncology Center of Moskovskiy District | Saint Petersburg, Russia | — |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02873819